Format

Send to

Choose Destination
Expert Opin Drug Deliv. 2010 Dec;7(12):1433-46. doi: 10.1517/17425247.2010.538047.

Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.

Author information

1
Vical, Inc., Pharmaceutical Sciences, 10390 Pacific Center Court, San Diego, CA 92121, USA. ssullivan@vical.com

Abstract

IMPORTANCE OF THE FIELD:

Many vaccines require the use of an adjuvant to achieve immunity. So far, few adjuvants have advanced successfully through clinical trials to become part of licensed vaccines. Vaxfectin® (Vical, CA, USA) represents a next-generation adjuvant with promise as a platform technology, showing utility with both plasmid DNA (pDNA) and protein-based vaccines.

AREAS COVERED IN THIS REVIEW:

This review describes the chemical, physical, preclinical and clinical development of Vaxfectin for pDNA-based vaccines. Also included is the preclinical development of Vaxfectin-adjuvanted protein- and peptide-based vaccines.

WHAT THE READER WILL GAIN:

The reader will gain knowledge of vaccine adjuvant development from bench to bedside.

TAKE HOME MESSAGE:

Vaxfectin has effectively boosted the immune response against a range of pDNA-expressed pathogenic antigens in preclinical models extending from rodents to non-human primates. In the clinic, Vaxfectin-adjuvanted pDNA-based H5N1 influenza vaccines have been shown to be well tolerated and to result in durable immune responses within the predicted protective range reported for protein-based vaccines.

PMID:
21118032
DOI:
10.1517/17425247.2010.538047
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center